The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.
Yu Liu,Wenjin Yin,Tingting Yan,Yueyao Du,Zhimin Shao,Jinsong Lu
DOI: https://doi.org/10.1185/03007995.2013.833088
2013-01-01
Current Medical Research and Opinion
Abstract:Objectives: Hormone-receptor (HR)-positive breast cancer is associated with a poor response to adjuvant chemotherapy. Thus, it is important to identify HR-positive patients who can benefit from chemotherapy and the Ki-67 index may help to predict chemotherapy efficacy in such populations. However, controversies exist regarding the prognostic and predictive role of Ki-67 and its exact cut-off value in HR-positive patients. Therefore, we conducted this study. Methods: The meta-analysis included 4512 patients in five trials. Due to different data formats provided by studies, we classified the trials into two groups to facilitate analysis. Group 1 included the PACS01, USON 01062, and IBCSG VIII and IX trials, while Group 2 included the BCIRG001, USON 01062, and IBCSG VIII and IX trials. Results: In Group 1, Ki-67 high patients had a worse prognosis in disease-free survival (DFS) than Ki-67 low counterparts (risk ratio [RR] 1.62, 95% confidence index [CI] 1.36-1.94, P50.001). In Group 2, Ki-67 high patients had a better prognosis in DFS (RR 0.53, 95% CI 0.45-0.61, P50.001) and overall survival (OS) (RR 0.32, 95% CI 0.25-0.42, P50.001). In Ki-67 high patients administered anthracycline/taxane-based chemotherapy, the experimental group (FAC -> T, AC -> TX) achieved a better DFS than the control group (FAC, AC! T, respectively) (RR 0.60, 95% CI 0.39-0.90, P 0.014). With a cut-off point >= 19%, Ki-67 high patients achieved a worse DFS (RR 1.49, 95% CI 1.28-1.72, P < 0.001). Conclusion: This study had limitations due to its retrospective nature and the lack of standardized Ki-67 measurement methods. Nevertheless, our findings indicate that Ki-67 high patients have a worse prognosis and may be more sensitive to anthracycline/taxane-based regimens. The ideal Ki-67 cut-off point for predicting chemosensitivity may be a certain value among a range of values >= 19% in HR-positive patients.